Inside Lonza Group: Revenue Trends, Strategic Moves, and Competitive Outlook

Switzerland — 22 July 2026

Lonza Group, a Swiss multinational manufacturing company, holds a near-ubiquitous position within the global B2B supplement industry. Through its Capsugel acquisition, the company is a dominant supplier of dosage forms, particularly hard capsules, and increasingly a contract development and manufacturing organisation (CDMO) for complex nutraceutical formulations. Its influence extends across the supply chain, making it a critical partner for many brands, from nascent startups to established players. Lonza's strategic moves often dictate trends in ingredient delivery and formulation.

Company Snapshot

Lonza Group AG is headquartered in Basel, Switzerland. For the fiscal year 2024, the company reported sales of CHF 6.7 billion, with approximately 30% derived from its Biologics and Small Molecules division, which includes nutraceutical CDMO services. Key brands include Capsugel® for capsule technologies, DRcaps® for delayed-release capsules, and Vcaps® for vegetarian alternatives. Lonza operates in over 100 markets globally and employs approximately 18,000 staff worldwide. Its extensive intellectual property portfolio underpins its market leadership in specialised dosage forms.

Strategic Position and Recent Moves

Lonza's strategic trajectory over the past two years has reinforced its position as an integrated solutions provider, moving beyond simple ingredient supply to comprehensive CDMO services. A significant move in late 2024 was the acquisition of a specialist botanical extraction facility in Germany for an estimated €85 million, enhancing its natural ingredient processing capabilities. This acquisition directly supports Lonza's strategy to offer end-to-end services, from raw material sourcing and extraction to finished dosage form manufacturing. Furthermore, in Q1 2025, Lonza announced a strategic partnership with a leading probiotics developer, establishing a joint venture to develop and commercialise next-generation spore-forming probiotic strains for targeted applications. This move, valued at an initial investment of CHF 50 million from Lonza, aims to capture a larger share of the rapidly expanding gut health market. The company also launched its new "Capsugel® Clean Label" range in Q3 2025, addressing growing consumer demand for transparent and additive-free supplement formulations. This initiative aligns with broader industry trends towards simplified ingredient lists and natural sourcing. Their recent investments in botanical processing and partnerships in probiotics demonstrate a clear intent to dominate high-value, complex formulation segments.

What Manufacturers Can Learn

Lonza Group's strategy offers clear insights into the future direction of the supplement market. Contract manufacturers should recognise the increasing demand for integrated, full-service solutions. Brands are seeking partners who can manage complex supply chains, from raw material to finished product, especially for specialised delivery systems like delayed-release capsules. This necessitates investment in advanced manufacturing capabilities and robust quality assurance. Ingredient suppliers, conversely, must differentiate through scientific substantiation and traceability. Lonza's focus on proprietary ingredients and advanced delivery methods underscores that generic commodities offer diminishing returns. The market is moving towards science-backed, differentiated ingredients delivered through innovative dosage forms. Suppliers who can't offer robust clinical data or novel applications will struggle to compete with Lonza's integrated offerings. Furthermore, the emphasis on clean label and sustainable sourcing indicates that environmental and ethical considerations are no longer niche, but core to market success.

Risks and Headwinds

Despite its strong market position, Lonza faces several risks. Regulatory scrutiny, particularly in key markets like the EU and US, remains a constant challenge, demanding continuous investment in compliance and quality systems. Competitively, while dominant in capsules, companies like Rousselot in collagen or DSM in vitamins maintain strong positions in their respective ingredient segments, posing a threat to Lonza's CDMO expansion. Furthermore, smaller, agile CDMOs can sometimes offer more flexible or niche services, potentially undercutting Lonza on specific projects. Economically, global supply chain disruptions and inflationary pressures on raw materials could impact profitability. Reputationally, any quality control issue, however minor, could severely damage trust in a company that is a backbone supplier to hundreds of brands. The significant capital expenditure required for its strategic acquisitions and facility upgrades also exposes Lonza to financial risk if market conditions shift unfavourably or integration efforts falter.

The B2B Verdict

Supplement businesses should certainly be watching Lonza Group closely. For many, partnering with Lonza, particularly for advanced dosage forms or complex formulations, is a strategic imperative given their technical expertise and scale. Competing directly in their core capsule market is largely unfeasible for most. However, smaller CDMOs and ingredient suppliers can thrive by focusing on niche areas, highly innovative ingredients, or exceptional customer service where Lonza's scale might be a disadvantage. Lonza's moves are a barometer for the industry's direction, making their strategy a valuable blueprint for understanding market evolution.